Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Cureus

Topical Tacrolimus for Seborrhoeic Dermatitis: A Systematic Review of Efficacy and Indirect Malignancy Evidence

5 affiliations
  1. 1Internal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, GBR
  2. 2Respiratory, Fairfield General Hospital, Greater Manchester, GBR
  3. 3Internal Medicine, Northampton General Hospital, Northampton, GBR
  4. 4Internal Medicine, University College London Hospitals NHS Foundation Trust, London, GBR
  5. 5Orthopaedics and Trauma, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GBR

Abstract

Seborrhoeic dermatitis (SD) is a chronic inflammatory skin disorder. Topical corticosteroids are effective for flares, but repeated facial use may thin the skin and cause telangiectasia or steroid-related facial eruptions. Topical tacrolimus is approved for atopic dermatitis (AD) in US and UK product labeling and is used off-label for SD. Its steroid-sparing potential must therefore be considered alongside the US Food and Drug Administration (FDA) boxed warning concerning a theoretical malignancy risk.

This systematic review evaluates the long-term efficacy, safety, and patient-reported outcomes associated with topical tacrolimus in SD, with particular focus on steroid-refractory and immunocompromised populations. Six databases were searched for English-language reports published from January 1, 2003, through June 5, 2025. Risk of bias was assessed using RoB 2, the Newcastle-Ottawa Scale (NOS), National Heart, Lung, and Blood Institute tools, or A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 according to study design. Clinical and methodological heterogeneity precluded a defensible new meta-analysis, so results were synthesized narratively.

Twenty-one reports were included: 8 direct SD reports, 10 indirect primary safety, pharmacokinetic, or skin structure reports, and 3 prior systematic reviews. Maintenance evidence was more consistent than induction evidence. In the largest SD maintenance trial, relapse occurred in 12 of 57 tacrolimus recipients and 23 of 57 ciclopiroxolamine recipients (hazard ratio (HR): 0.44, 95% confidence interval (CI): 0.22-0.89). Transient burning or tingling was the principal adverse effect. No included SD study was large or long enough to assess malignancy. In AD, the largest synthesis reported a tacrolimus-specific odds ratio for any cancer of 0.99 (95% credible interval: 0.89-1.09), although some observational cohorts reported cutaneous T-cell lymphoma (CTCL) signals. Protopathic bias, disease severity, and surveillance are plausible explanations but do not exclude a causal association.

Topical tacrolimus appears useful for selected patients with facial SD, with the strongest direct evidence supporting twice-weekly maintenance after disease control. Long-term malignancy conclusions remain indirect for SD and should be communicated with appropriate uncertainty. Patient-preference and quality-of-life evidence is insufficient for firm conclusions.

Related

  1. High tacrolimus intrapatient variability is associated with graft loss after kidney transplantation: a systematic review and meta-analysis
    Kittiphan Chienwichai, Pannawat Mongkolrattanakul, Arunchai Chang
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref
  2. Clinical efficacy of topical 0.1% tacrolimus in patients with corneal neovascularization: A prospective, multicenter, randomized controlled pilot trial.
    Myung-Sun Song, Youngsub Eom, Ikhyun Jun +1
    Advances in ophthalmology practice and researchPeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineEurope PMCPMC
  3. Efficacy and Safety of Moderate-Dose Glucocorticoids with Tacrolimus in High-Risk Membranous Nephropathy: A Real-World Comparison of Three Immunosuppressive Regimens.
    Lu Sui, Yutong Ma, Xintian Yu +7
    Drug design, development and therapyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  4. Relevance‐Based Score for MIPD Model Selection: Systematic Review and External Evaluation of popPK Tacrolimus Models in Adult Transplant Recipients
    Samuel Baroudi, Bénédicte Franck, Jean-Baptiste Woillard +3
    CPT: Pharmacometrics and Systems PharmacologyPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsHAL
  5. Use of Tacrolimus and Voclosporin as Induction Therapy in Lupus Nephritis: A Focused Systematic Review and Meta-Analysis of Randomized Evidence
    Urvi Zala, Rushi Patel, Jacob Thompson +1
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
BibTeX
@article{ojo2026topical,
  title = {{Topical Tacrolimus for Seborrhoeic Dermatitis: A Systematic Review of Efficacy and Indirect Malignancy Evidence}},
  author = {Ethel O Ojo and Success T Oyibo and Itawosim Orim and Sinmiloluwa Oke and Alberta Bow and Daniel E Onobun},
  journal = {Cureus},
  year = {2026},
  month = oct,
  doi = {10.7759/cureus.117866},
  url = {https://doi.org/10.7759/cureus.117866},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Topical Tacrolimus for Seborrhoeic Dermatitis: A Systematic Review of Efficacy and Indirect Malignancy Evidence
AU  - Ethel O Ojo
AU  - Success T Oyibo
AU  - Itawosim Orim
AU  - Sinmiloluwa Oke
AU  - Alberta Bow
AU  - Daniel E Onobun
PY  - 2026
DA  - 2026/10/13
JO  - Cureus
DO  - 10.7759/cureus.117866
UR  - https://doi.org/10.7759/cureus.117866
AB  - Seborrhoeic dermatitis (SD) is a chronic inflammatory skin disorder. Topical corticosteroids are effective for flares, but repeated facial use may thin the skin and cause telangiectasia or steroid-related facial eruptions. Topical tacrolimus is approved for atopic dermatitis (AD) in US and UK product labeling and is used off-label for SD. Its steroid-sparing potential must therefore be considered alongside the US Food and Drug Administration (FDA) boxed warning concerning a theoretical malignancy risk.  This systematic review evaluates the long-term efficacy, safety, and patient-reported outcomes associated with topical tacrolimus in SD, with particular focus on steroid-refractory and immunocompromised populations. Six databases were searched for English-language reports published from January 1, 2003, through June 5, 2025. Risk of bias was assessed using RoB 2, the Newcastle-Ottawa Scale (NOS), National Heart, Lung, and Blood Institute tools, or A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 according to study design. Clinical and methodological heterogeneity precluded a defensible new meta-analysis, so results were synthesized narratively.  Twenty-one reports were included: 8 direct SD reports, 10 indirect primary safety, pharmacokinetic, or skin structure reports, and 3 prior systematic reviews. Maintenance evidence was more consistent than induction evidence. In the largest SD maintenance trial, relapse occurred in 12 of 57 tacrolimus recipients and 23 of 57 ciclopiroxolamine recipients (hazard ratio (HR): 0.44, 95% confidence interval (CI): 0.22-0.89). Transient burning or tingling was the principal adverse effect. No included SD study was large or long enough to assess malignancy. In AD, the largest synthesis reported a tacrolimus-specific odds ratio for any cancer of 0.99 (95% credible interval: 0.89-1.09), although some observational cohorts reported cutaneous T-cell lymphoma (CTCL) signals. Protopathic bias, disease severity, and surveillance are plausible explanations but do not exclude a causal association.  Topical tacrolimus appears useful for selected patients with facial SD, with the strongest direct evidence supporting twice-weekly maintenance after disease control. Long-term malignancy conclusions remain indirect for SD and should be communicated with appropriate uncertainty. Patient-preference and quality-of-life evidence is insufficient for firm conclusions.
SN  - 2168-8184
ER  -